Results for tag: "Tumor Microenvironment"

The Tumor Microenvironment (TME) is a complex network of cells, proteins, and other molecules that interact with cancer cells and influence their behavior. It is an important factor in the development and progression of cancer, and is increasingly being studied in the context of oncology drugs. TME research has revealed that cancer cells are not the only players in the development of cancer. The TME is composed of a variety of cell types, including immune cells, fibroblasts, and endothelial cells, as well as extracellular matrix components, cytokines, and growth factors. These components interact with cancer cells to influence their behavior, such as proliferation, invasion, and metastasis. The TME is also an important factor in drug response. Drugs that target the TME can be used to enhance the efficacy of existing cancer therapies, as well as to develop new treatments. For example, drugs that target the TME can be used to reduce tumor-associated inflammation, which can improve the efficacy of chemotherapy and radiation therapy. Companies in the TME market include AstraZeneca, Merck, Novartis, Pfizer, and Roche. Show Less Read more